News Releases

Date	Title and Summary	View
Sep 02, 2020	Janssen to Discontinue Pimodivir Influenza Development Program
Sep 02, 2020	Janssen to Present Latest Research in Multiple Sclerosis at MSVirtual2020: 8th Joint ACTRIMS-ECTRIMS Meeting
Aug 21, 2020	U.S. FDA Approves New DARZALEX® (daratumumab)-Based Combination Regimen for Patients with Relapsed/Refractory Multiple Myeloma Approval broadens DARZALEX label to include fifth treatment option in the relapsed/refractory setting and represents the eighth approved indication for DARZALEX HORSHAM, Pa., August 20, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the U.S.
Aug 20, 2020	Johnson & Johnson to Participate in the 18th Annual Morgan Stanley Virtual Global Healthcare Conference
Aug 19, 2020	Johnson & Johnson to Acquire Momenta Pharmaceuticals, Inc., Expanding Janssen's Leadership in Novel Treatments for Autoimmune Diseases $6.5 Billion Acquisition Through an All-Cash Tender Offer of $52.50 Per Momenta Share Lead Asset Nipocalimab Provides Opportunity for Janssen to Deliver Transformative Treatments in Autoantibody-Driven Autoimmune Diseases Momenta's Cambridge, Massachusetts, Presence Increases J&J Footprint and
Aug 17, 2020	Johnson & Johnson to Participate in Wells Fargo 2020 Virtual Healthcare Conference
Aug 14, 2020	Johnson & Johnson to Participate in Barclays Global Consumer Staples Virtual Conference
Aug 05, 2020	Johnson & Johnson Announces Agreement with U.S. Government for 100 Million Doses of Investigational COVID-19 Vaccine Company working to ensure broad global access to COVID-19 vaccine candidate, following approval from regulators NEW BRUNSWICK, N.J., Aug. 5, 2020 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) (the Company) today announced its Janssen Pharmaceutical Companies have entered into an agreement with
Aug 03, 2020	Janssen Announces U.S. FDA Approval of SPRAVATO® (esketamine) CIII Nasal Spray to Treat Depressive Symptoms in Adults with Major Depressive Disorder with Acute Suicidal Ideation or Behavior
Jul 30, 2020	U.S. FDA Grants Ethicon Breakthrough Device Designation for Monarch-enabled NeuWave Microwave Ablation Technology